Abstract B49: Development and characterization of a novel CA9 targeting dual-antibody T-cell engager for renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm18-b49
Abstract: The survival benefit of checkpoint immunotherapies is currently limited, with de novo and acquired resistance to therapy occurring in over 75% of patients. A major mechanism of resistance accounting for these poor responses is a… read more here.
Keywords: ca9; immunology; dual antibody; cell ... See more keywords